The IAS-USA Annual Update on HIV Management in Chicago, Illinois (Offered In-Person and Virtually)

Last Modified: May 1, 2026 @ 11:19 AM

Program Description

Join us in Chicago for one of the most anticipated IAS–USA annual courses, where science, clinical expertise, and advances in HIV care come together. This dynamic, in-person course at the David Rubenstein Forum at the University of Chicago will convene leading experts and frontline clinicians for an exciting day of learning, discussion, and practical clinical insights. This course is also offered virtually, providing flexible access for clinicians to participate from anywhere.

Stay on the cutting edge of HIV medicine with timely updates and lively case-based discussions. The course will address key topics in HIV and sexually transmitted infection (STI) prevention and treatment, including updated approaches to preexposure prophylaxis (PrEP) selection, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their impact on metabolic complications, aging-related concerns in people with HIV, and complex antiretroviral therapy (ART) clinical decision-making. Faculty will also discuss substance use disorders (SUDs), drug-drug interactions involving long-acting and newer agents, and investigational drugs and treatment strategies in the pipeline.

Don’t miss the opportunity to engage with expert faculty and peers and stay at the forefront of HIV management.

Assessment of Needs

Rapid advances in HIV prevention, ART, comorbidity management, and investigational treatment strategies require ongoing education for clinicians caring for people with HIV. This course will address the implications of new information on strategies for the clinical management of HIV and related comorbidities. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing ART in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Describe the most current data from recent HIV scientific conferences, including research on new and investigational antiretroviral drugs
• Apply current data and recommendations for HIV and STI prevention, including selection of appropriate PrEP options
• Describe the role of GLP-1 RAs and their impact on metabolic syndromes in people with HIV
• Identify clinical considerations related to aging with HIV, including cognitive decline, mental health, and frailty
• Recognize and manage clinically relevant drug-drug interactions, including those involving long-acting and newer HIV therapies
• Apply evidence-based recommendations for the prevention and management of SUDs and comorbidities in people with HIV

Preliminary Topics

• What’s new in HIV and STI prevention
• GLP-1 RAs and their impact on metabolic syndrome
• Aging with HIV: cognitive decline, mental health, and frailty
• Difficult cases in ART
• Management of SUDs in people with HIV
• Drug-drug interactions, including long-acting and other new drugs
• Investigational drugs and treatment strategies in the pipeline

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.